Loading...
Loading...
In a report published Wednesday, Morgan Stanley analyst Suzanne E. Stein initiated coverage on
IMS HealthIMS with an Equal-Weight rating and $26.00 price target.
In the report, Morgan Stanley noted, “IMS is an attractive way for investors to participate in the growing healthcare analytics end-market. We see valuation as fair, given our outlook for mid-single-digit top-line growth, modest margin expansion, and strong free cash flow.”
IMS Health closed on Tuesday at $25.21.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in